ClinicalTrials.Veeva

Menu

Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis

University Hospital Center (CHU) logo

University Hospital Center (CHU)

Status

Unknown

Conditions

Metastatic Melanoma

Study type

Observational

Funder types

Other

Identifiers

NCT05510466
RECHMPL22_0016

Details and patient eligibility

About

Currently, therapeutic options in BRAF mutated melanoma with brain metastasis occurring after achievement of a good control of extracerebral secondary lesions by a first line combined targeted therapy (TT) are limited. In this setting, the addition of an anti PD1 agent to TT may be proposed as a second line strategy. This observational survey aims at investigating the benefit/risk ratio of this triple combination in a small cohort of patients.

Enrollment

18 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Metastatic melanoma BRAF mutated
  • Initially treated by a doubled targeted therapy anti BRAF/anti MEK
  • With an intra cerebral progression of the tumor
  • Whom we add an check point inhibitor anti PD1, combined with the double targeted therapy
  • between 01/2019 et 01/2022

Exclusion criteria

  • Other condition

Trial contacts and locations

1

Loading...

Central trial contact

Olivier DEREURE, MD, PhD; Marie Louise Jeanne, resident

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems